文献速递免疫规划传染病防控与疫情报告

皮内注射灭活脊髓灰质炎疫苗分剂量的针头适配器:巴基斯坦免疫原性与项目可行性评估

Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan.
PubMed 文献 · Vaccine · 2017-05-04

在巴基斯坦卡拉奇6-12月龄儿童中比较BCG针筒与两种皮内装置接种1/5剂灭活脊髓灰质炎疫苗的免疫应答,并评估入户接种可行性。BCG针筒与装置A免疫应答相似,装置B较低(PV1 53% vs 77%/69%,PV2 53% vs 68%/74%,PV3 56% vs 76%/70%,均p<0.05)。接种员报告装置B装填有问题,II期无其他操作挑战。

要点

  • BCG针筒与装置A接种1/5剂IPV后三个血清型免疫应答相似。
  • 装置B免疫应答较低:PV1 53% vs BCG针筒77%与装置A69%,PV2 53% vs 68%与74%,PV3 56% vs 76%与70%,均p<0.05。
  • 接种员报告装置B装填有问题,II期未报告其他操作挑战。

核心结论

  • BCG针筒与装置A接种1/5剂IPV免疫应答相似,装置B较低(p<0.05)。
  • 接种员报告装置B装填有问题,II期无其他操作挑战。
  • 分剂量IPV提供了一种节省剂量的替代全剂量IPV的方案。

研究设计与样本

  • I期:卡拉奇452名6-12月龄儿童随机接受BCG针筒、装置A或装置B接种1剂分剂量IPV。
  • II期:在单日入户接种活动中评估项目可行性,评价接种员体验。

主要发现

  • 免疫应答定义为基线滴度≤362的儿童接种后28天血清转阳或脊灰中和抗体滴度四倍升高。
  • PV1免疫应答:BCG针筒34/44(77%)、装置A 31/45(69%)、装置B 16/30(53%),p<0.05。
  • PV2免疫应答:BCG针筒53/78(68%)、装置A 61/83(74%)、装置B 42/80(53%),p<0.05。
  • PV3免疫应答:BCG针筒58/76(76%)、装置A 56/80(70%)、装置B 43/77(56%),p<0.05。
  • 接种员在两个阶段均报告装置B装填有问题;II期未报告其他操作挑战。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Administration of 1/5th dose of Inactivated poliovirus vaccine intradermally (fIPV) provides similar immune response as full-dose intramuscular IPV, however, fIPV administration with BCG needle and syringe (BCG NS) is technically difficult. We compared immune response after one fIPV dose administered with BCG NS to administration with intradermal devices, referred to as Device A and B; and assessed feasibility of conducting a door-to-door vaccination campaign with fIPV. In Phase I, 452 children 6-12months old from Karachi were randomized to receive one fIPV dose either with BCG NS, Device A or Device B in a health facility. Immune response was defined as seroconversion or fourfold rise in polio neutralizing antibody titer 28days after fIPV among children whose baseline titer ≤362. In Phase II, fIPV was administered during one-day door-to-door campaign to assess programmatic feasibility by evaluating vaccinators' experience. For all three poliovirus (PV) serotypes, the immune response after BCG NS and Device A was similar, however it was lower with Device B (34/44 (77%), 31/45 (69%), 16/30 (53%) respectively for PV1; 53/78 (68%), 61/83 (74%), 42/80 (53%) for PV2; and; 58/76 (76%), 56/80 (70%), 43/77 (56%) for PV3; p<0.05 for all three serotypes). Vaccinators reported problems filling Device B in both Phases; no other operational challenges were reported during Phase II. Use of fIPV offers a dose-saving alternative to full-dose IPV.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Saleem AF, Mach O, Yousafzai MT, et al. Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan. Vaccine. 2017. PMID: 28479178. doi:10.1016/j.vaccine.2017.04.075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。